Sight Diagnostics
Last updated: Jul 31, 2026
Sight Diagnostics developed compact blood-analysis systems that use automated sample preparation, optical imaging and computer vision to produce rapid hematology results from small blood samples. Its later strategy broadened toward AI analysis of live immune-cell behavior, but public reporting indicates that the company suspended operations and was effectively closed in 2026.
Visit WebsiteCompany Overview
Sight Diagnostics was an Israeli medical-device and diagnostics company founded in 2011. Its flagship Sight OLO system was designed to perform a complete blood count from a small venous or finger-prick sample, using proprietary sample preparation and high-resolution imaging rather than the workflow of a conventional centralized hematology laboratory. The platform digitized blood cells into large image datasets and used embedded machine-learning models to classify and count cell populations. This was a credible deep-tech proposition: the company reported an FDA-cleared OLO product and a CE-marked system, while third-party coverage described a compact analyzer that could return CBC results in minutes and operate with less laboratory infrastructure than traditional systems.
The commercial problem was meaningful but difficult. Hospitals, emergency departments, outpatient clinics and smaller laboratories value short turnaround times, simple collection and decentralized testing, particularly when a laboratory is distant or overloaded. The product could also reduce dependence on manual microscopy and make routine hematology more accessible in settings with limited laboratory capacity. Sight raised a reported $71 million Series D in 2020, bringing reported cumulative financing to approximately $124 million at that point, and earlier coverage described deployments and regulatory progress. Those milestones demonstrate substantial technical and commercialization effort, but they do not establish durable revenue, broad reimbursement, or a sustainable installed base.
Sight later attempted a major strategic pivot from a relatively mature CBC use case toward an immune-intelligence platform. The company described a multidisciplinary fluorescent microscopy platform, proprietary live-cell data and AI-derived immune signatures intended to address infectious disease, oncology and autoimmune conditions. Its official website and company profile describe a reusable hardware-and-test-kit platform that measures functional immune-cell behavior, and a reported collaboration with Shaare Zedek Medical Center supported access to clinical data and a dedicated R&D laboratory. These are relevant technical and clinical-development signals, but the newer claims remained dependent on prospective validation, regulatory clearance and adoption in specific indications; they should not be treated as established clinical performance.
The current operating status is the decisive diligence issue. Calcalist reported in April 2026 that the board dismissed approximately 20 remaining employees after earlier layoffs and described the company as at risk of closure. A subsequent public post by a former employee stated that Sight had officially closed, had declined from roughly 300 people to 20 during its pivot, and had not brought its newer emergency-department product to market. The official website remains online, so the domain is still the canonical public reference, but the available evidence supports classifying the operating company as defunct or wound down rather than as an active Series D startup. The underlying patents, regulatory work, datasets, hardware designs and clinical relationships may still have strategic or acquisition value, but any such value would require separate confirmation of asset ownership, maintenance, transferability and continuing support obligations.
For defense and national-security readers, the technology has a genuine but bounded dual-use rationale. A compact blood analyzer or live-cell diagnostic platform could support expeditionary medicine, forward triage, remote clinics, outbreak response and casualty-care logistics where laboratory turnaround is constrained. The value would be medical readiness and reduced dependence on rear-echelon infrastructure, not offensive capability. However, no reliable public evidence establishes defense procurement, military deployment or validation in combat conditions. The company’s closure also means that technical promise cannot be equated with an available product, service organization or strategically relevant operating platform.
Dual-Use Assessment
Sight's core diagnostic capabilities have substantive civilian and defense-medical adjacency: rapid hematology and potentially richer immune-state information could support forward triage, expeditionary medicine, remote military clinics, humanitarian response and infectious-disease screening where centralized laboratories are unavailable. The dual-use case is operational medical support rather than weapons technology. No reliable public source confirms military procurement, deployment or defense-specific validation, and the company's reported 2026 shutdown materially reduces current deployment value.
Strategic Fit Assessment
Sight demonstrated significant technical ambition, regulatory progress and historical fundraising, but the latest public evidence indicates that operations were suspended and the company was effectively closed in 2026 after layoffs and an unsuccessful attempt to commercialize a newer immune-diagnostics product. The record is therefore relevant as a distressed technology and intellectual-property diligence case, not as an active startup priority signal. Any strategic interest would require confirmation of surviving assets, patent ownership, product support, clinical data rights, regulatory status and the identity of a continuing operating entity.
Strategic Value to U.S.-Israel Alliance
The technology could have supported medical readiness by shortening diagnostic cycles and reducing dependence on centralized laboratories, especially in remote or austere environments. That strategic value is presently conditional: public evidence does not show defense adoption, and the reported shutdown means there may be no functioning supplier, field-support team or maintained product. Potential value now lies in transferable IP, validated hardware and data, or an acquihire/asset transaction, subject to legal and technical diligence.
Key Technologies
- Automated preparation of low-volume venous and capillary blood samples
- High-resolution optical and fluorescent live-cell imaging
- Computer-vision segmentation and classification of blood-cell populations
- Embedded machine-learning inference for rapid hematology analysis
- AI-derived functional immune-cell and immune-signature analysis
- Compact point-of-care analyzer and test-kit integration
Use Cases & Applications
- Rapid complete blood count testing in emergency departments
- Decentralized hematology testing in outpatient and small laboratories
- Finger-prick or low-volume testing where venous laboratory collection is difficult
- Forward or expeditionary medical triage when centralized laboratory access is limited
- Remote-clinic and humanitarian diagnostics in resource-constrained settings
- Infectious-disease and outbreak-response screening support
- Research and clinical-trial measurement of immune-cell behavior
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile. The editorial policy explains how profiles are researched, where automated drafting is used, and how corrections work.
This record lists 6 public references used for company identity, status, positioning, or material-claim review.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- sightdx.com Public source used for profile verification.
- LinkedIn company page Public source used for profile verification.
- techcrunch.com Public source used for profile verification.
- calcalistech.com Public source used for profile verification.
- LinkedIn company page Public source used for profile verification.
- ivc-online.com Public source used for profile verification.
- Profile update timestamp Last updated in the Claw & Talon database on Jul 31, 2026.
Investor Lens
What this entry is
Defunct or wound down
Why it may matter
Sight Diagnostics may matter as a Health & BioTech entry with not currently an investable standalone company for Israeli technology research.
How an independent investor should read this
Not currently an investable standalone company. Read this profile as a starting point for independent verification, not as a recommendation or suitability assessment.
Evidence to verify
- Verify current status
- Verify technical claims
- Verify regulatory/export-control issues
Main investor questions
- Is this entry a benchmark, buyer, ecosystem node, acquired asset, or strategic reference rather than a live startup opportunity?
- What does this reference clarify about buyers, sector structure, public-market context, or strategic demand?
- Does the dual-use claim map to actual commercial and government/defense/resilience buyer evidence?
- What evidence would change the thesis or show that the profile is stale?
What not to infer
- Inclusion does not imply endorsement.
- Inclusion does not imply allocation availability or current fundraising.
- Scores do not indicate investment suitability or expected returns.
- Strategic importance does not automatically imply venture return potential.
Diligence questions
- What evidence verifies Sight Diagnostics's current customer traction, deployment status, and revenue concentration?
- Which technical claims are independently demonstrable today, and which remain roadmap or pilot-stage assertions?
- Where does the product create real defense, intelligence, critical-infrastructure, or emergency-response value beyond ordinary commercial adoption?
- What regulatory, procurement, and buyer-adoption constraints could slow deployment in strategic or government-adjacent markets?
- Is the company a live venture opportunity, a mature strategic reference, an acquired asset, or primarily a market-mapping entry?
Related sector
See the Health & BioTech sector page for market context, related subcategories, and other Israeli companies in this part of the database.
Related companies
Need a diligence readout?
Use the profile and related checklists as a starting point. If the decision needs more context, request a company screen, founder-call prep, diligence memo, or sector readout.